Induction therapy for cryptococcal meningitis in HIV patients (first-line drug combination)?

Induction therapy for cryptococcal meningitis in HIV patients (first-line drug combination)?

• A. Amphotericin B (liposomal) plus flucytosine
• B. Fluconazole monotherapy
• C. Voriconazole alone
• D. Amphotericin B deoxycholate plus fluconazole

Answer: (A)

Rapid reduction of fungal burden in the CSF is the main aim of induction therapy for HIV-associated cryptococcal meningitis. The best first-line induction regimen combines amphotericin B in its liposomal form with flucytosine because they work together to kill the fungus more quickly than either drug alone. Amphotericin B directly disrupts fungal cell membranes, while flucytosine impedes DNA synthesis, and their synergy accelerates CSF sterilization, which is linked to lower mortality. The liposomal form is preferred because it is less nephrotoxic and tolerable at effective doses, allowing better CNS penetration and patient safety in a severely ill population. After this induction period, therapy typically moves to a consolidation phase with high-dose fluconazole and then maintenance therapy, but starting with this combination yields the strongest early response. Fluconazole monotherapy, voriconazole alone, or amphotericin B deoxycholate with fluconazole do not provide the same rapid, synergistic clearance or tolerability, making them less suitable as first-line induction regimens.

Rapid reduction of fungal burden in the CSF is the main aim of induction therapy for HIV-associated cryptococcal meningitis. The best first-line induction regimen combines amphotericin B in its liposomal form with flucytosine because they work together to kill the fungus more quickly than either drug alone. Amphotericin B directly disrupts fungal cell membranes, while flucytosine impedes DNA synthesis, and their synergy accelerates CSF sterilization, which is linked to lower mortality. The liposomal form is preferred because it is less nephrotoxic and tolerable at effective doses, allowing better CNS penetration and patient safety in a severely ill population. After this induction period, therapy typically moves to a consolidation phase with high-dose fluconazole and then maintenance therapy, but starting with this combination yields the strongest early response. Fluconazole monotherapy, voriconazole alone, or amphotericin B deoxycholate with fluconazole do not provide the same rapid, synergistic clearance or tolerability, making them less suitable as first-line induction regimens.